Pacemaker News and Research RSS Feed - Pacemaker News and Research

St. Jude Medical's net sales increase 2% in first quarter 2014

St. Jude Medical's net sales increase 2% in first quarter 2014

St. Jude Medical, Inc. today reported sales and net earnings for the first quarter ended March 29, 2014. [More]
UCL scientists find new way to artificially control paralyzed muscles using light

UCL scientists find new way to artificially control paralyzed muscles using light

​A new way to artificially control muscles using light, with the potential to restore function to muscles paralysed by conditions such as motor neuron disease and spinal cord injury, has been developed by scientists at UCL and King's College London. [More]

Study compares two types of heart valve technologies

Among patients undergoing aortic valve replacement using a catheter tube, a comparison of two types of heart valve technologies, balloon-expandable or self-expandable valve systems, found a greater rate of device success with the balloon-expandable valve, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. [More]

FDA approves Allure Quadra Cardiac Resynchronization Therapy Pacemaker

St. Jude Medical, Inc., a global medical device company, today announced approval from the U.S. Food and Drug Administration (FDA) for the Allure Quadra™ Cardiac Resynchronization Therapy Pacemaker (CRT-P), which provides additional pacing innovations for physicians to treat patients with heart failure. [More]
Researchers identify genetic defect that causes a subset of irritable bowel syndrome

Researchers identify genetic defect that causes a subset of irritable bowel syndrome

Is irritable bowel syndrome (IBS) caused by genetics, diet, past trauma, anxiety? All are thought to play a role, but now, for the first time, researchers have reported a defined genetic defect that causes a subset of IBS. The research was published in the journal Gastroenterology. [More]
FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has approved the expansion of BIOTRONIK's ongoing ProMRI trial. The new phase of the trial (Phase C) will study the company's ProMRI technology in implantable cardioverter-defibrillator (ICD) devices. [More]

Respicardia receives Best Innovation of 2014 award from CRT and CV Pipeline for remedē System

Respicardia, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the Best Innovation of 2014 from Cardiovascular Research Technologies (CRT) and CV Pipeline for the remedē System, the first and only implantable device for the treatment of central sleep apnea. [More]
New coating extends lifespan of nanoelectronics, may help develop small implanted medical devices

New coating extends lifespan of nanoelectronics, may help develop small implanted medical devices

The debut of cyborgs who are part human and part machine may be a long way off, but researchers say they now may be getting closer. [More]
Rhythmicity of activity linked to bipolar mania

Rhythmicity of activity linked to bipolar mania

Circadian rhythm disturbances are associated with bipolar disorder, and particularly with mania, indicate study findings. [More]
G. Alexander Patterson honored with 2014 Earl Bakken Scientific Achievement Award

G. Alexander Patterson honored with 2014 Earl Bakken Scientific Achievement Award

The Society of Thoracic Surgeons today awarded G. Alexander Patterson, MD with the 2014 Earl Bakken Scientific Achievement Award during the Society's 50th Annual Meeting. [More]

London hospital implants world’s first leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced the first post-approval implant of the Nanostim™ leadless pacemaker in the U.K. The world's first retrievable leadless pacemaker was implanted at St. Bartholomew's Hospital in London by Professor Richard Schilling. [More]

Most high-risk CV devices approved without clinical data

Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA. [More]

St. Jude Medical reports net sales of $1.422 billion in fourth quarter 2013

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and full year ended Dec. 28, 2013. [More]
ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients. [More]
Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Deep brain stimulation uses a surgical implant similar to a pacemaker to send electrical impulses to the brain. [More]

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th). [More]
VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

IMRIS Inc. and MRI Interventions, Inc. today announced that Cook Children's Medical Center in Fort Worth, Texas, is the first U.S. pediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilizing the combination of MRI Interventions' ClearPoint Neuro Intervention System and an IMRIS VISIUS Surgical Theatre for real-time intraoperative image guidance and procedure visualization. [More]
Siemens Healthcare to introduce new angiography system at RSNA 2013

Siemens Healthcare to introduce new angiography system at RSNA 2013

At the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America, December 1-6 in Chicago, Siemens Healthcare (booth #1934, South Building/Lakeside Center at McCormick Place, Hall A) will introduce a new angiography system optimized for broad clinical utilization. [More]

HeartWare International acquires CircuLite

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has acquired CircuLite, Inc. – developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent. [More]

Heart failure patients may benefit from advanced treatment by heart specialists

New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists - something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure. [More]